HCQ

DRUG10 trials

Sponsors

Abramson Cancer Center at Penn Medicine, Peking University First Hospital, Peking Union Medical College Hospital, Qilu Hospital of Shandong University, Novartis Pharmaceuticals

Conditions

Arthritis, RheumatoidBreast CancerCOVID 19CoVID-19Covid-19Covid19Hepatocellular CarcinomaNasopharyngeal Carcinoma

Phase 1

Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC

TerminatedNCT02013778

Abramson Cancer Center at Penn MedicineHepatocellular Carcinoma

Start: 2013-11-30End: 2019-02-28Updated: 2020-04-20

Phase 2

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

RecruitingNCT04841148

Abramson Cancer Center at Penn MedicineBreast Cancer

Start: 2021-06-01End: 2028-05-01Target: 96Updated: 2026-04-09

Phase 3

Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease

CompletedNCT04358081

Novartis PharmaceuticalsCovid-19

Start: 2020-05-01End: 2020-07-27Updated: 2021-10-11

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

CompletedNCT04408456

Post Graduate Institute of Medical Education and Research, ChandigarhCoVID-19

Start: 2020-03-01End: 2020-07-31Updated: 2020-08-04

Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression

CompletedNCT04491994

UNICEFCovid19, Progression

Start: 2020-04-10End: 2020-05-31Updated: 2020-08-21

Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia

WithdrawnNCT04528927

Abderrahmane Mami HospitalCOVID 19, Patients Hospitalized

Start: 2020-05-15End: 2020-07-15Updated: 2020-08-27

Phase 4

The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment

CompletedNCT03855007

Qilu Hospital of Shandong UniversityArthritis, Rheumatoid

Start: 2016-01-01End: 2023-10-31Updated: 2023-11-18

Unknown Phase

Combination Therapy Prevents the Relapse of RA

Peking University First HospitalRecurrence (Disease Attribute)

Start: 2015-10-31End: 2020-09-30Target: 240Updated: 2020-06-22

Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus

CompletedNCT02842814

Peking Union Medical College HospitalSystemic Lupus Erythematosus

Start: 2016-10-31End: 2022-09-28Updated: 2022-10-03

Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

RecruitingNCT06389201

Affiliated Hospital of Nantong UniversityNasopharyngeal Carcinoma

Start: 2024-08-01End: 2034-08-01Target: 30Updated: 2025-02-18

Related Papers

Abstract PD5-02: 5-year outcomes and ctdna findings in the clever trial targeting disseminated dormant tumor cells

Clinical Cancer Research2026-02-17

Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal (PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China.

2025-01-025 citations

Efficacy, safety, and cost-effectiveness of triple therapy in preventing relapse in rheumatoid arthritis: A randomized controlled trial (ESCoRT study)

Chinese Medical Journal2022-09-204 citations

The efficacy, safety and cost-effectiveness of hydroxychloroquine, sulfasalazine, methotrexate triple therapy in preventing relapse among patients with rheumatoid arthritis achieving clinical remission or low disease activity: the study protocol of a randomized controlled clinical Trial (ESCoRT study)

BMC Medical Informatics and Decision Making2021-03-045 citations

Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis.

2019-05-2113 citations